TrialJournal of thrombosis and haemostasis : JTH2019

Pharmacokinetics of idarucizumab and its target dabigatran in patients requiring urgent reversal of the anticoagulant effect of dabigatran.

Stephan Glund et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.